Next Article in Journal
Healthcare Workers Occupationally Exposed to Ionizing Radiation Exhibit Altered Levels of Inflammatory Cytokines and Redox Parameters
Next Article in Special Issue
Signals Getting Crossed in the Entanglement of Redox and Phosphorylation Pathways: Phosphorylation of Peroxiredoxin Proteins Sparks Cell Signaling
Previous Article in Journal
Structural and Biochemical Insights into the Reactivity of Thioredoxin h1 from Chlamydomonas reinhardtii
Previous Article in Special Issue
Piecing Together How Peroxiredoxins Maintain Genomic Stability
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessReview
Antioxidants 2019, 8(1), 11;

Peroxiredoxins in Cancer and Response to Radiation Therapies

Department of Internal Medicine, Section on Molecular Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA
Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA
The Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30332, USA
Author to whom correspondence should be addressed.
Received: 28 November 2018 / Revised: 23 December 2018 / Accepted: 25 December 2018 / Published: 1 January 2019
(This article belongs to the Special Issue The Role of Peroxiredoxins in Cancer)
PDF [1765 KB, uploaded 1 January 2019]


Peroxiredoxins have a long-established cellular function as regulators of redox metabolism by catalyzing the reduction of peroxides (e.g., H2O2, lipid peroxides) with high catalytic efficiency. This activity is also critical to the initiation and relay of both phosphorylation and redox signaling in a broad range of pathophysiological contexts. Under normal physiological conditions, peroxiredoxins protect normal cells from oxidative damage that could promote oncogenesis (e.g., environmental stressors). In cancer, higher expression level of peroxiredoxins has been associated with both tumor growth and resistance to radiation therapies. However, this relationship between the expression of peroxiredoxins and the response to radiation is not evident from an analysis of data in The Cancer Genome Atlas (TCGA) or NCI60 panel of cancer cell lines. The focus of this review is to summarize the current experimental knowledge implicating this class of proteins in cancer, and to provide a perspective on the value of targeting peroxiredoxins in the management of cancer. Potential biases in the analysis of the TCGA data with respect to radiation resistance are also highlighted. View Full-Text
Keywords: peroxiredoxin; radiation resistance; ionizing radiation; oxidative stress; transcriptomics; proteomics; TCGA; NCI-60 peroxiredoxin; radiation resistance; ionizing radiation; oxidative stress; transcriptomics; proteomics; TCGA; NCI-60

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Forshaw, T.E.; Holmila, R.; Nelson, K.J.; Lewis, J.E.; Kemp, M.L.; Tsang, A.W.; Poole, L.B.; Lowther, W.T.; Furdui, C.M. Peroxiredoxins in Cancer and Response to Radiation Therapies. Antioxidants 2019, 8, 11.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Antioxidants EISSN 2076-3921 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top